AVITA Medical (NASDAQ:RCEL) Given Buy Rating at D. Boral Capital
AVITA Medical (NASDAQ:RCEL – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $22.00 target price on the stock. D. Boral Capital’s price target indicates a potential upside of 126.57% from the […]
More Stories
Sphere 3D (NASDAQ:ANY) Coverage Initiated at StockNews.com
StockNews.com assumed coverage on shares of Sphere 3D (NASDAQ:ANY – Free Report) in a report issued on Tuesday morning. The...
Mizuho Cuts Align Technology (NASDAQ:ALGN) Price Target to $250.00
Align Technology (NASDAQ:ALGN – Free Report) had its target price reduced by Mizuho from $295.00 to $250.00 in a report...
Wedbush Reaffirms “Outperform” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Wedbush restated their outperform rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) in a research note released on...
THG (LON:THG) Price Target Cut to GBX 45 by Analysts at JPMorgan Chase & Co.
THG (LON:THG – Free Report) had its price objective decreased by JPMorgan Chase & Co. from GBX 49 ($0.63) to...
Shore Capital Reaffirms “Buy” Rating for Gamma Communications (LON:GAMA)
Shore Capital reissued their buy rating on shares of Gamma Communications (LON:GAMA – Free Report) in a report released on...
JPMorgan Chase & Co. Raises Lloyds Banking Group (LON:LLOY) Price Target to GBX 71
Lloyds Banking Group (LON:LLOY – Free Report) had its price target upped by JPMorgan Chase & Co. from GBX 62...